Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death

Ran Bi1, Yuyou Deng1, Chao Tang1

  • 1Department of Urology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

Oncology Reports
|October 1, 2020
PubMed

Insights

Andrographolide (Andro) sensitizes resistant renal cancer cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) therapy. This combination effectively inhibits cancer cell viability, proliferation, and migration, offering potential for renal cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells.
  • Certain cancer types, including renal carcinoma cells (RCCs), exhibit resistance to TRAIL-mediated apoptosis.
  • Developing strategies to overcome TRAIL resistance is crucial for effective cancer therapy.

Purpose of the Study:

  • To identify an effective combination regimen to overcome TRAIL resistance in renal cancer cells.
  • To investigate the potential of andrographolide (Andro) as a TRAIL sensitizer in RCCs.

Main Methods:

  • Human renal carcinoma cells (RCCs) were treated with TRAIL and andrographolide (Andro).
  • Cell viability was assessed using MTS assays, proliferation by EdU incorporation, and clonogenic/migration abilities were evaluated.
  • Cell cycle arrest and senescence were analyzed by flow cytometry.
  • Apoptosis-related protein expression and TRAIL receptor (DR4, DR5) levels were determined by immunoblot assay.

Main Results:

  • Andro counteracted TRAIL resistance in RCCs, suppressing cell viability, proliferation, and migration in a dose-dependent manner.
  • Combined TRAIL and Andro treatment induced significant G2/M phase cell cycle arrest and senescence.
  • Andro restored TRAIL signaling, activating pro-apoptotic caspases and upregulating the TRAIL receptor DR4.
  • DR4 upregulation by Andro contributed to its role as a TRAIL sensitizer.

Conclusions:

  • Combined treatment with andrographolide and TRAIL demonstrates significant therapeutic potential against renal cancer.
  • Andrographolide effectively sensitizes TRAIL-resistant renal cancer cells by upregulating DR4 and restoring TRAIL-induced apoptosis.
  • This combination therapy offers a promising strategy for overcoming TRAIL resistance in renal cancer treatment.

Related Concept Videos